GeneDx (WGS) Competitors $91.61 +1.82 (+2.03%) Closing price 07/3/2025 01:00 PM EasternExtended Trading$90.65 -0.96 (-1.05%) As of 07/3/2025 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock WGS vs. GH, OPCH, RDNT, BTSG, SHC, SGRY, CON, PRVA, VCYT, and ADUSShould you be buying GeneDx stock or one of its competitors? The main competitors of GeneDx include Guardant Health (GH), Option Care Health (OPCH), RadNet (RDNT), BrightSpring Health Services (BTSG), Sotera Health (SHC), Surgery Partners (SGRY), Concentra Group Holdings Parent (CON), Privia Health Group (PRVA), Veracyte (VCYT), and Addus HomeCare (ADUS). These companies are all part of the "healthcare" industry. GeneDx vs. Its Competitors Guardant Health Option Care Health RadNet BrightSpring Health Services Sotera Health Surgery Partners Concentra Group Holdings Parent Privia Health Group Veracyte Addus HomeCare GeneDx (NASDAQ:WGS) and Guardant Health (NASDAQ:GH) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk. Does the media favor WGS or GH? In the previous week, GeneDx had 8 more articles in the media than Guardant Health. MarketBeat recorded 19 mentions for GeneDx and 11 mentions for Guardant Health. Guardant Health's average media sentiment score of 0.72 beat GeneDx's score of 0.43 indicating that Guardant Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeneDx 8 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Guardant Health 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend WGS or GH? GeneDx presently has a consensus price target of $90.13, suggesting a potential downside of 1.62%. Guardant Health has a consensus price target of $53.76, suggesting a potential upside of 6.99%. Given Guardant Health's stronger consensus rating and higher probable upside, analysts plainly believe Guardant Health is more favorable than GeneDx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GeneDx 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75Guardant Health 0 Sell rating(s) 0 Hold rating(s) 21 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is WGS or GH more profitable? GeneDx has a net margin of -11.69% compared to Guardant Health's net margin of -53.82%. GeneDx's return on equity of 10.17% beat Guardant Health's return on equity.Company Net Margins Return on Equity Return on Assets GeneDx-11.69% 10.17% 5.51% Guardant Health -53.82%N/A -26.77% Which has more volatility & risk, WGS or GH? GeneDx has a beta of 2.01, meaning that its stock price is 101% more volatile than the S&P 500. Comparatively, Guardant Health has a beta of 1.44, meaning that its stock price is 44% more volatile than the S&P 500. Which has stronger valuation and earnings, WGS or GH? GeneDx has higher earnings, but lower revenue than Guardant Health. GeneDx is trading at a lower price-to-earnings ratio than Guardant Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGeneDx$305.45M8.56-$52.29M-$1.41-64.97Guardant Health$739.02M8.42-$436.37M-$3.39-14.82 Do institutionals and insiders hold more shares of WGS or GH? 61.7% of GeneDx shares are held by institutional investors. Comparatively, 92.6% of Guardant Health shares are held by institutional investors. 29.6% of GeneDx shares are held by insiders. Comparatively, 6.1% of Guardant Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryGeneDx beats Guardant Health on 9 of the 16 factors compared between the two stocks. Get GeneDx News Delivered to You Automatically Sign up to receive the latest news and ratings for WGS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding WGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart WGS vs. The Competition Export to ExcelMetricGeneDxMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.61B$7.31B$5.53B$9.05BDividend YieldN/A2.78%5.24%4.03%P/E Ratio-64.9727.9427.5220.22Price / Sales8.5632.39421.02118.64Price / Cash89.5322.0136.8958.07Price / Book10.476.698.045.67Net Income-$52.29M$233.06M$3.18B$249.13M7 Day Performance0.56%3.33%2.90%3.28%1 Month Performance32.42%3.72%3.70%5.55%1 Year Performance216.88%37.40%36.15%21.12% GeneDx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)WGSGeneDx2.2108 of 5 stars$91.61+2.0%$90.13-1.6%+227.2%$2.61B$305.45M-64.971,200Insider TradeGap UpGHGuardant Health3.7456 of 5 stars$52.04+2.3%$53.76+3.3%+76.9%$6.30B$739.02M-15.352,021Insider TradeOPCHOption Care Health4.3657 of 5 stars$32.48+0.7%$35.50+9.3%+11.5%$5.28B$5.00B26.198,088Positive NewsRDNTRadNet3.6791 of 5 stars$56.91-0.4%$69.60+22.3%-5.2%$4.29B$1.83B-132.3511,021BTSGBrightSpring Health Services1.6305 of 5 stars$23.59+0.2%$24.90+5.6%+95.5%$4.14B$11.27B84.2535,000SHCSotera Health3.0002 of 5 stars$11.12-1.8%$16.00+43.9%+0.8%$3.21B$1.10B139.023,000SGRYSurgery Partners2.6015 of 5 stars$22.23+1.3%$33.56+50.9%-6.1%$2.81B$3.11B-14.5315,000CONConcentra Group Holdings Parent2.5486 of 5 stars$20.59-2.6%$28.50+38.4%N/A$2.71B$1.90B15.3711,250PRVAPrivia Health Group4.2389 of 5 stars$23.00+4.5%$27.77+20.7%+30.4%$2.68B$1.74B191.681,140High Trading VolumeVCYTVeracyte3.6016 of 5 stars$27.03-1.3%$40.90+51.3%+28.1%$2.14B$445.76M65.93790ADUSAddus HomeCare4.9651 of 5 stars$115.19+0.1%$142.57+23.8%-4.7%$2.12B$1.15B26.0049,703 Related Companies and Tools Related Companies GH Competitors OPCH Competitors RDNT Competitors BTSG Competitors SHC Competitors SGRY Competitors CON Competitors PRVA Competitors VCYT Competitors ADUS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:WGS) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. AI has recently turned the tech world on its head. And th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeneDx Holdings Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share GeneDx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
